Original Article

Estimating the Lifetime and Age-Conditional Risk of an HIV Diagnosis in Iran, 2011-2015

Abstract

Background: According to the importance of infectious diseases, especially HIV, the purpose of this study was to estimate lifetime and age-conditional risks of HIV diagnosis in Iran.

Methods: We used vital statistics, HIV surveillance and census data for 2011-2015 to calculate Age-specific HIV diagnosis and non-HIV death rates. These rates then converted to the probability of an HIV diagnosis considering the competing risk. Finally, the probabilities were applied to a hypothetical cohort of 10 million live births. The lifetime and age-conditional risk of HIV diagnosis in the total and general population of Iran were calculated by Dev Can software (version 6.7.4).

Results: Lifetime risk was 0.084% (95% CI: 0.081-0.088) or one in 1183 for females and 0.21% (95% CI: 0.201- 0.211) or one in 483 for males in the total population. In the general population lifetime risk for men was 0.069% (95% CI: 0.066-0.072) or 1 in 1454 men and 0.066% (95%CI: 0.063-0.069) or one in 1523 for women. In the total and general population, the 10-yr age-conditional risk of HIV diagnosis showed that the highest risk of an HIV diagnosis is related to 30-yr -olds.

Conclusion: The estimated risks differed based on gender, age, and type of population. Paying close attention to these differences is critical for infection control planning and policies.

1. World Health Organization (2020). Fact sheet HIV/AIDS 2019. https://www.who.int/news-room/fact-sheets/detail/hiv-aids
2. Ministry of Health and Medical Education (2017). Islamic Republic of Iran AIDS Progress Report. Tehran, Iran.
3. Nasirian M, Fahimfar N, Hgahdoost AK, et al (2014). Report of HIV estimation and projection in IRAN. Centre for Disease Control Ministry of Health and Medical Education, Tehran, Iran.
4. Joulaei H, Lankarani KB, Kazerooni PA, et al (2017). Number of HIV-infected cases in Iran: True or just an iceberg. Indian J Sex Transm Dis AIDS, 38(2):157-162.
5. Zarei E, Khabiri R, Tajvar M, et al (2018). Knowledge of and attitudes toward HIV/AIDS among Iranian women. Epidemiol Health, 40:e2018037.
6. Akbari M, Akbari M, Naghibzadeh-Tahami A, et al (2016). Prevalence of HIV/AIDS among Iranian Prisoners: A Review Article. Addict Health, 8(3):195-206.
7. Khajehkazemi R, Osooli M, Sajadi L, et al (2013). HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey. Sex Transm Infect, 3(Suppl 3):iii29-32.
8. Sharifi H, Mirzazadeh A, Shokoohi M, et al (2018). Estimation of HIV incidence and its trend in three key populations in Iran. PloS one, 13(11):e0207681.
9. Rahimi-Movaghar A, Amin-Esmaeili M, Haghdoost AA, et al (2012). HIV prevalence amongst injecting drug users in Iran: a systematic review of studies conducted during the decade 1998-2007. Int J Drug Policy, 23(4):271-8.
10. Wolfe D, Malinowska-Sempruch K (2004). Illicit Drug Policies and the Global HIV Epidemic Effects of UN and National Government Approaches. Working paper commissioned by the HIV/AIDS Task Force of the Millennium Project.
11. Hess KL, Hu X, Lansky A, et al (2017). Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol, 27(4):238-243.
12. Seyed Ahmad S, Behnam F, Minoo M, et al (2017). Prevalence of HIV in a Prison of Tehran by Active Case Finding. Iran J Public Health, 46(3): 431–432.
13. Foroughi M, Moayedi-Nia S, Shoghli A, et al (2017). Prevalence of HIV, HBV and HCV among street and labour children in Tehran, Iran. Sex Transm Infect, 93(6):421-423.
14. Bagheri Amiri F, Mostafavi E, Mirzazadeh A (2016). HIV, HBV and HCV Coinfection Prevalence in Iran--A Systematic Review and Meta-Analysis. PloS One, 11(3):e0151946.
15. Miri R, Ahmadi Ghezeldasht S, Mosavat A, et al (2017). No Evidence of HIV Infection Among the General Population of Mashhad, Northeast of Iran. Jundishapur Journal of Microbiology, 10 (3); e43655.
16. Ahmad AS, Ormiston-Smith N, Sasieni PD (2015). Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer, 112(5):943-7.
17. Hall HI, An Q, Hutchinson AB, Sansom S (2008). Estimating the lifetime risk of a diagnosis of the HIV infection in 33 states, 2004-2005. J Acquir Immune Defic Syndr, 49(3):294-7.
18. Adih W, Hu X, Campsmith M, et al (2010). Estimated lifetime risk for diagnosis of HIV infection among Hispanic/Latinos—37 States and Puerto Rico, 2007. MMWR Morb Mortal Wkly Rep, 59(40):1297-301.
19. Bosh KA, Laffoon BT (2010). Lifetime and Age-Conditional Risk of Human Immunodeficiency Virus Diagnosis, Missouri, 1998–2007. Sex Transm Dis, 37(12):764-6.
20. Sharifi H, Shokoohi M, Ahmad RafieiRad A, et al (2017). Methamphetamine use among Iranian youth: a population-based knowledge, attitude, and practice study. Subst Use Misuse, 52(9):1232-1239.
21. Haghdoost AA, Mostafavi E, Mirzazadeh A, et al (2011). Modelling of HIV/AIDS in Iran up to 2014. Journal of AIDS and HIV Research, 3(12):231-239
Files
IssueVol 50 No 5 (2021) QRcode
SectionOriginal Article(s)
Published2021-04-30
DOI https://doi.org/10.18502/ijph.v50i5.6122
Keywords
Lifetime risk Age-conditional risk HIV Population Iran

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Nasirian M, Mahboobi M, Maracy MR. Estimating the Lifetime and Age-Conditional Risk of an HIV Diagnosis in Iran, 2011-2015. Iran J Public Health. 50(5):1048-1055.